Researchers have identified a rare Florida fungus, Galerina indica, that produces both psilocybin and deadly amatoxins.
Reported in Current Biology on November 11, this “dark magic mushroom” is the first known species to synthesize both a psychedelic compound and a lethal liver toxin, presenting a significant risk for accidental ingestion.
- Amatoxins are potent hepatotoxins—compounds that cause severe liver damage—often found in death cap mushrooms.
- Psilocybin is a psychoactive alkaloid currently under investigation in clinical trials for its potential in treating depression and anxiety.
- Dual-toxicity means a user seeking a psychedelic experience could inadvertently ingest a lethal dose of liver-destroying chemicals.
Chemist and fungal biologist Andrew Kunik first identified Galerina indica in 2025 while conducting research on a decaying, moss-covered palm trunk in a central Florida wetland. At the time, Kunik was a post-baccalaureate researcher within the University of Florida lab of fungal biologist Matthew Smith, and he said that there were no prior records of this species appearing in that area. “It’s quite rare and unusual,” Kunik said.
While previous researchers had identified the mushroom’s physical appearance and DNA signatures, its complete chemical profile remained unknown. Genetic analysis conducted by the team confirmed that the mushroom contains the pathways required to produce both amatoxins and psilocybin. This discovery challenges the long-held assumption in mycology that fungi typically produce one or the other, but not both.
The presence of these disparate chemical compounds in a single organism suggests complex evolutionary history. The researchers discovered that the ancestors of these mushrooms likely acquired the genes for toxin production through horizontal gene transfer—a process where organisms exchange DNA with unrelated species, similar to how bacteria share antibiotic resistance.
“This finding shows that there’s a lot more diversity in [fungal] chemistry and the ways that they’re combined than we had really thought about,” said Anne Pringle, a mycologist at the University of Wisconsin–Madison. While G. indica retains both sets of genes, other related species identified by Kunik have evolved differently; one produces psilocybin but lacks amatoxins, while another produces neither.
| Fungal Species | Contains Psilocybin | Contains Amatoxins |
|---|---|---|
| Galerina indica | Yes | Yes |
| Galerina species 1 | Yes | No |
| Galerina species 2 | No | No |
The primary public health concern regarding this discovery is the extreme difficulty of identifying wild mushrooms.
Anyone who consumes a wild mushroom and experiences symptoms such as severe abdominal pain, nausea, vomiting, or diarrhea must seek emergency medical care immediately. There is no home remedy for amatoxin poisoning; clinical management requires hospitalization, often involving liver function monitoring and, in severe cases, liver transplantation.
Pringle notes that people often immediately ask, “Can I eat it?” when they discover a new mushroom. “I’m always so uncomfortable with that question and that conversation. And this paper confirms that, in fact, you should be uncomfortable.”
